Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment.
Central nervous system (CNS) manifestations are not rare in pediatric rheumatic diseases. They may be a relatively common feature of the disease, as in systemic lupus erythematosus (SLE) and Behçet's disease. Direct CNS involvement of a systemic rheumatic disease, primary CNS vasculitis, indirect involvement secondary to hypertension, hypoxia and metabolic changes, and drug associated adverse events may all result in CNS involvement. We have reviewed the CNS manifestations of SLE, Behçet's disease, Henoch-Schönlein purpura, polyarteritis nodosa, juvenile idiopathic arthritis, juvenile ankylosing spondylitis, familial Mediterranean fever, scleroderma, sarcoidosis, Wegener's granulomatosis, Takayasu's arteritis, CINCA syndrome, Kawasaki disease, and primary CNS vasculitis; and adverse CNS effects of anti-rheumatic drugs in pediatric patients. The manifestations are diverse; ranging from headache, seizures, chorea, changes in personality, depression, memory and concentration problems, cognitive impairment, cerebrovascular accidents to coma, and death. The value of cerebrospinal fluid (CSF) examination (pleocytosis, high level of protein), auto-antibodies in serum and CSF, electroencephalography, neuroimaging with computerized tomography, magnetic resonance imaging, SPECT, PET, and angiography depends on the disease. Brain biopsy is gold standard for the diagnosis of CNS vasculitis, however it may be inconclusive in 25% of cases. A thorough knowledge of the rheumatic diseases and therapy-related adverse events is mandatory for the management of a patient with rheumatic disease and CNS involvement. Severe CNS involvement is associated with poor prognosis, and high mortality rate. High dose steroid and cyclophosphamide (oral or intravenous) are first choice drugs in the treatment; plasmapheresis, IVIG, thalidomide, and intratechal treatment may be valuable in treatment-resistant, and serious cases.
Department of Pediatrics, Pediatric Nephrology and Rheumatology Unit, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Ali
A
Duzova
Aysin
A
Bakkaloglu
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D010372:Pediatrics; D010956:Plasmapheresis; D012216:Rheumatic Diseases / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use; D020293:Vasculitis, Central Nervous System / Q000175:diagnosis / Q000209:etiology / Q000628:therapy
D000927:Anticonvulsants; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D013256:Steroids; D013792:Thalidomide; D003520:Cyclophosphamide